Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Ratna1, or this one...


Immunoglobulin A (IgA) is an antibody blood protein that's part of your immune system. Your body makes IgA and other type of antibodies to help fight off sickness. Having an IgA deficiency means that you have low levels of or no IgA in your blood. https://www.hopkinsmedicine.org/health/conditions-and-diseases/immunoglobulin-a-deficiency The body makes different antibodies, or immunoglobulins, to fight different things. For example, the antibody for chickenpox isn't the same as the antibody for mononucleosis. Sometimes, the body may even mistakenly make antibodies against itself, treating healthy organs and tissues like foreign invaders. This is called an autoimmune disease. https://kidshealth.org/en/parents/test-immunoglobulins.html HOW DO VACCINES WORK??? A vaccine works by training the immune system to recognize and combat pathogens, either viruses or bacteria. To do this, certain molecules from the pathogen must be introduced into the body to trigger an immune response. These molecules are called antigens, and they are present on all viruses and bacteria. https://www.publichealth.org/public-awareness/understanding-vaccines/vaccines-work/ WHAT’S THE DIFFERENCE BETWEEN IG [Immuno Globulin] AND VACCINES? IG is a substance made up of antibodies that are naturally made by the body to provide protection from certain diseases. A vaccine is a substance made up of actual viruses or bacteria that stimulate the body to make more antibodies. https://www.verywellhealth.com/what-is-immune-globulin-1760124 The addition of VIP was associated with a significant increase in the production of IgA, whereas IgG levels were significantly reduced. Both these effects were restricted to LPMC. LDA showed that the IgA-enhancing effect was associated with an increase in the number of IgA-producing precursor cells and with variation in the regulatory phenomena involved in IgA production. https://pubmed.ncbi.nlm.nih.gov/8119526/ Vasoactive intestinal peptide (VIP), a peptide produced by immune cells, exerts a wide spectrum of immunological functions that control the homeostasis of the immune system. In the last decade, VIP has been clearly identified as a potent anti-inflammatory factor, both in innate and adaptive immunity. https://pubmed.ncbi.nlm.nih.gov/16312132/ COULD RLF TAKE A CHUNK OUT OF THE VACCINE MARKET??? The global vaccine market size accounted for $32,462 million in 2019, and is expected to reach $54,150 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.

https://www.globenewswire.com/news-release/2020/12/09/2141957/0/en/Global-Vaccine-Market-to-Reach-US-57-Billion-by-2025-Fostered-by-Sudden-Outbreak-of-COVID-19-By-IMARC-Group.html